We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
SARS‐CoV‐2 reinfection in a cancer patient with a defective neutralizing humoral response.
- Authors
Borgogna, Cinzia; De Andrea, Marco; Griffante, Gloria; Lai, Alessia; Bergna, Annalisa; Galli, Massimo; Zehender, Gianguglielmo; Castello, Luigi; Ravanini, Paolo; Cattrini, Carlo; Mennitto, Alessia; Gennari, Alessandra; Gariglio, Marisa
- Abstract
The patient's blood was only available on Day 110 and resulted negative for the presence of SARS-CoV-2 genome by droplet digital PCR analysis. Keywords: cancer patient; neutralization humoral response; reinfection; SARS-CoV-2 EN cancer patient neutralization humoral response reinfection SARS-CoV-2 6444 6446 3 10/18/21 20211201 NES 211201 Since August 2020, a series of cases of reinfection by a phylogenetically distinct variant of SARS-CoV-2 have been reported, raising pertinent questions on the heterogeneity of the natural immune response to SARS-CoV-2 infection that may not uniformly confer protective immunity to all individuals.1-5 Specifically, reinfection seems more likely to occur in individuals whose immune system has been weakened by underlying comorbidities or therapies.6-8 Here, we report a case of a 52-year-old male patient suffering from transitional cell carcinoma of the renal pelvis and ureter who was infected at two separate times with two genetically distant SARS-CoV-2 strains, with the reappearance of the first strain four months after the first infection. SARS-CoV-2 reinfection in a cancer patient with a defective neutralizing humoral response.
- Subjects
HUMORAL immunity; SARS-CoV-2; REINFECTION; MEDICAL personnel; CANCER patients
- Publication
Journal of Medical Virology, 2021, Vol 93, Issue 12, p6444
- ISSN
0146-6615
- Publication type
Case Study
- DOI
10.1002/jmv.27200